Sobre
Laboratoire de recherche du vieillissement. Drug discovery, biomarkers, cellular reprogramming, aging biology.
Sede
San Francisco, California, USA
Fundada
2013
Tipo
Laboratório
Ecossistemas
1
Identidade jurídica
- Nome jurídico
- Calico Life Sciences LLC
- Status
- Ativo
- Verificado em
- 2026-08-30
- Próxima revisão
- 2026-11-30
Missão
“Harness advanced technologies to increase human healthspan.”
Áreas de foco
Aging biologyDrug discoverySenolyticsCellular reprogrammingBiomarkers
Participação em ecossistemas
Roteiro estratégico
2025 Q4
● Em andamentoABBV-CLS-628 enters Phase 2 for ADPKD
Calico reported on 2 October 2025 that its anti-PAPP-A monoclonal antibody had received FDA Fast Track designation and was enrolling an ongoing Phase 2 trial for autosomal dominant polycystic kidney disease. It is not described as a senolytic.
Longevidade e Antienvelhecimento
2026 Q4
◯ PlanejadoCombination therapy trials initiate
Multiple senolytic agents + reprogramming regimen.
Longevidade e Antienvelhecimento
2028 Q2
◯ PlanejadoAge reversal demonstrated 5+ years
Biomarker validation. Aging reversal in humans.
Longevidade e Antienvelhecimento